Rasagiline improves quality of life in p
β
Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T
π
Article
π
2006
π
John Wiley and Sons
π
English
β 164 KB
π 1 views
The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P